P16‐55: Additional effects of macrolides on steroid pulse therapy in patients with acute exacerbation of interstitial lung disease

• DOI: 10.1111/resp.14150_964
• Publication Date: 2021-11-20T04:04:45Z
• Authors: Yasuhiko Nakamura; Sakae Homma; Matsuko Yabe; Hiroshige Shimizu; Takuma Isshiki; Susumu Sakamoto; Kazutoshi Shibuya; Akira Iyoda; Kazuma Kishi; Ryo Nagasawa; Yu Hara; Kota Murohashi; Yusuke Saigusa; Y Nishikawa; Meiro Tanaka; Ayako Aoki; Kou Chin; Hiroki Watanabe; Nobuyuki Horita; Keisuke Watanabe; Nobuaki Kobayashi; Makoto Kudo; Takeshi Kaneko; Eiko Suzuki; Jun Ikari; Nozomi Tanaka; Masaki Suzuki; Rie Anazawa; Ayako Shimada; Yusuke Katsumata; M. Katsumata; Seiichiro Sakao; Koichiro Tatsumi; Takuji Suzuki

analysis, the administration of antifibrotic agents was a significant independent predictor 6-month survival (odds ratio, 3.18; p=0.045).Conclusion: Antifibrotic treatment starting at onset AE may improve in patients with AE-IPF.